Drug Monitoring
10
3
4
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Lupus Nephritis
Microsampling for Therapeutic Drug Monitoring of Oral Oncolytics in Oncology Patients
Individualized Antiretroviral Therapy
TDM Guided Early Optimization of ADAL in Crohn's Disease
Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels
Influence of HLA-DQA1*05 Genotype in Adults With Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring.
Plasma Protein Binding and PK/PD of Total and Unbound Temocillin Non-ICU Patients
Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units
Quality of Life and Efficacy Evaluation of Patient Self-monitoring Their Oral Anticoagulation Therapy